Product Overview

Proven Efficacy

Metastatic Colorectal Cancer (mCRC)

• Superior response rates and equivalent survival compared to 5-FU/LV in first-line mCRC^1,2,3

 
Adjuvant Stage III (Dukes' C) Colon Cancer

• Superior response rates and equivalent survival compared to 5-FU/LV in first-line mCRC¹

 
Metastatic Breast Cancer (mBC)

• Proven efficacy regardless of HER2 status⁴
• 25.6% response rate in anthracycline- and taxane-pretreated mBC patients^5-8
• XELODA plus docetaxel delivers rapid response and superior survival⁹

 

Manageable Safety Profile

Adverse Events are Manageable and, in Most Cases, Reversible

• Dose modification does not appear to compromise efficacy across indications^9,13,14,15

 
Preferential Activation and Prolonged Exposure—A Unique Cytotoxic Option^10-12

• Learn more about XELODA's preferential activation and prolonged cytotoxic exposure

 

• Click here to view a video describing XELODA's unique mechanism of action (MOA).

 

REFERENCES

1. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19(8):2282-2292.
2. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19(21):4097-4106.
3. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-flourouracil and leucovorin: integrated efficacy data and novel analyses from two large, radomised, phasse III trials. Br J Cancer. 2004;90:1190-1197.
4. Tykerb [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
5. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001;92(9):2267-2272.
6. Blum JL, Savin MA, Edelman G, et al. Long term disease control in taxane-refractory metastatic breasdt cancer treated with nab paclitaxel [abstract] J Clin Oncol. 2004;22(July 15 suppl):543.
7. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant mestatic breast cancer. J Clin Oncol. 1998;6(10)3362-3368.
8. Modi S, Currie VE, Seidman AD, et al. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer. 2005;6(1):55-60.
9. O'Shaughnessy JA. Superior survival with the combination of docetaxel and capecitabine compared to docetaxel alone in anthracycline-pretreated metastatic breast cancer patients. Am J Oncol Rev. 2002;1(5):280-285.
10. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 200;45:291-297.
11. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine, carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-1281.
12. Thomas DM, Zalcberg JR. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol. 1998;25:887-895.
13. Data on file (Ref. 111-036), Hoffmann-La Roche Inc., Nutley, NJ 07110
14. Cassidy J, Twelves C, Van Cutsem Em, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13;566-575.
15. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812-2823.